Main Article Content
Background: In many chronic diseases such as IPF and COPD, accelerated aging and telomere shortening have been studied. Different studies have shown that these individuals have shorter telomere lengths than controls; this can be a marker of the progression and outcome of the disease. So far, a few studies have been evaluated the telomere length in sarcoidosis. In this study we try to determine the telomere length in sarcoidosis patients and compare with control subjects.
Objective: Our aim is to compare telomere length in sarcoidosis patients and normal population.
Methods: We select 58 sarcoidosis patients who were visited in the outpatient clinic of sarcoidosis in Masih Daneshvari Hospital.58 healthy control subjects were selected and tried to be sex-matched and age-matched with±2 years of age. Telomere length was measured by quantitative real time PCR as described by Cawthon on peripheral blood sample. The telomere repeat copy number (T) to single-gene copy number(S) ratio was calculated using the comparative Ct method.
Results: The mean and standard deviation of telomere length in the patient and control group was 0.65 ± 0.05 and 0.72 ± 0.07 respectively. There was a statistically significant difference between the two groups. (P = 0.031).
Conclusion: Sarcoidosis is an inflammatory disease that can involve many organs. Like other chronic diseases, aging phenomenon occurs in that; which led to decrease cellular and tissue telomere length. This article demonstrates shorter telomere length in Iranian sarcoidosis patients compared to normal population.
2) Elizabeth V. Arkema and Yvette C. Cozier. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis 2018, Vol. 9(11) 227–240.
3) Cozier YC, Berman JS, Palmer JR,Boggs DA , Serlin DM, Rosenberg L . Sarcoidosis in black women in the United States: Data from the black women’s health study. Chest. 2011; 139:144–150.
4) Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Resp J. 2008; 31:372–379.
5) Harley CB, Vaziri H, Counter CM and Allsopp RC. The telomere hypothesis of cellular aging. Exp Gerontol 1992; 27: 375-82.
6) Blackburn EH. Structure and function of telomeres. Nature 1991; 350: 569-73.
7) Dillin A, Gottschling DE, Nyström T. "The good and the bad of being connected: the integrons of aging". Curr Opin Cell Biol. 2013; 26: 107–12.
8) Holohan B, Wright WE, Shay JW. Cell biology of disease: Telomeropathies: an emerging spectrum disorder. J Cell Biol 2014; 205 (3): 289- 99.
9) Jang JS, Choi YY, Lee WK, Choi JE, Cha SI, Kim YJ, et al. Telomere length and the risk of lung cancer. Cancer Sci 2008; 99 (7): 1385- 9.
10) Chan SW, Blackburn EH. New ways not to make ends meet: telomerase, DNA damage proteins and heterochromatin. Oncogene 2002; 21: 553-63.
11) Houben JM, Mercken EM, Ketelslegers HB, Bast A, Wouters EF, Hageman GJ, et al. Telomere shortening in chronic obstructive pulmonary disease. Respir Med 2009; 103 (2): 230- 6.
12) Von Zglinicki T. Telomeres and replicative senescence: is it only length that counts? Cancer Lett 2001; 168:111-6.
13) Von Zglinicki T.Role of oxidative stress in telomere length regulation and replicative senescence. Ann N Y Acad Sci 2000; 908: 99-110.
14) Von Zglinicki T, Saretzki G, Docke W, Lotze C. Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence? Exp Cell Res 1995; 220: 86-193.
15) Hemann M, Strong M, Hao L, Greider C. The Shortest Telomere, Not Average Telomere Length, Is Critical for Cell Viability and Chromosome Stability. Cell, 2001;107, 67–77.
16) Lee J, Sandford A, Man P, Sin D. Is the aging process accelerated in chronic obstructive pulmonary disease? Curr Opin Pulm Med. 2011; 17:90–97.
17) Amsellem V, Gary-Bobo G, Marcos E, Maitre B, Chaar V, Validire P and et al. Telomere Dysfunction Causes Sustained Inflammation in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med .2001; 1358–1366.
18) Kropski JA, Blackwell TS,Loyd JA.The genetic basis of idiopathic pulmonary fibrosis. ERJ Express. 2015.
19) Sadr M, Noori Mugahi1 S, Hassanzadeh G, Nadji S, Kiani A, Abedini A, et al. Telomere Shortening in Blood Leukocytes of Patients with Chronic Obstructive Pulmonary Disease. Tanaffos 2015; 14(1): 10-16.
20) Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135 (1): 173- 80.
21) Liu JP.Molecular mechanisms of ageing and related diseases. Clin Exp Pharmacol Physiol 2014; 41 (7): 445- 58.
22 ) Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years of older. Lancet 2003; 361: 393-5.
23) Kropski JA, Blackwell TS,Loyd JA.The genetic basis of idiopathic pulmonary fibrosis. ERJ Express. 2015.
24) Maeda T, Guan J , Higuchi Y , Oyama J , Makino N. Aging-Related Alterations of Subtelomeric Methylation in Sarcoidosis Patients. Journal of Gerontology Journal of Gerontology 2009; 752–760.
25) Guan J, Maeda T, Sugano M, Oyama J, Higuchi J, Suzuki T and et al. An Analysis of Telomere Length in Sarcoidosis Journal of Gerontology: BIOLOGICAL SCIENCES Copyright 2007 by The Gerontological Society of America.2007; 1199–120.
26) Thompson I; Liu B; Sen H; Dumitriu B; Calado R; Hirani S,et al. Telomere Length of peripheral leukocytes is shortened in Ocular Sarcoidosis patients . ARVO Annual Meeting. 2013, Volume 54, Issue 15.
27) ) Studdy P, Bird R, James DG et al: Serum ACE in sarcoidosis and other granulomatous disorders. Lancet, 1978; 1441-54.
28) Lieberman J: Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis. Am J Med, 1975; 59: 365–72.
29) Silverstein E, Friedland, J Lyons HA et al: Evaluation of ACE in granulomatous lymph nodes and serum in sarcoidosis: Clinical and possible pathogenic significance. Ann NY Acad Sci, 1976; 278: 498–513
30)Kahkouee S, Samadi K, Alai A,Abedini A, Rezaiian L. Serum ACE Level in Sarcoidosis Patients with Typical and Atypical HRCT Manifestation. Pol J Radiol, 2016; 81: 458-461
31) Wong J , De Vivo I, Lin X, Fang S, Christiani D. The Relationship between Inflammatory Biomarkers and Telomere Length in an Occupational Prospective Cohort Study.Plos one. January 2014. Volume9. Issue 1.
32) Pedroso DC, Miranda-Furtado CL, Kogure GS, Meola J, Okuka M, Silva C, et al. Inflammatory biomarkers and telomere length in women with polycystic ovary syndrome. Fertil Steril. 2015 Feb;103(2):542-7.
33) Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30: e47.